Program
Azacitidine
Also written as “azacitidine”, “Azacitidine (AZA)” and “Eganelisib in combination with azacitidine”.
Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Hematologic Neoplasms · Lymphoma, T-Cell, led by 9 companies.
Drug pageAzacitidine: every studyMany companies study it; this page follows only the 27 they lead. All 441 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 161 open or running | phase 4since Sep 13, 2010 | Oct 31, 2003 | none ahead |
| Takedaits history only | 30 open or running | phase 3since Aug 30, 2017 | May 28, 2009 | none ahead |
| Hikma Pharmaceuticalsits history only | 21 open or running | phase 1since Mar 11, 2024 | Mar 11, 2024 | none ahead |
| Bioniche Pharma USAits history only | 10 open or running | phase 1since Jun 25, 2010 | Jun 25, 2010 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 2since Feb 7, 2020 | Feb 7, 2020 | none ahead |
| Merck | 10 open or running | phase 2since Nov 24, 2014 | Nov 24, 2014 | none ahead |
| Nanexa ABits history only | 10 open or running | phase 1since May 11, 2021 | May 11, 2021 | none ahead |
| Nob Hill Therapeuticsits history only | 11 open or running | phase 2since Sep 10, 2026 | Sep 10, 2026 | Jul 13, 2029phase 2 · NCT07864584 |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Oct 4, 2006 | Oct 4, 2006 | none ahead |
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical, Hoffmann-La Roche, Roche-Genentech, Takeda Development Center Americas and argenx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 24, 2014First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT02303782
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Merck leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02303782Leukemia, Myeloid, Acute | 2 | Withdrawn | Mar 2016 | 0 |
How it is read
Names in the registry
- “Azacitidine”, 36 entries
- “azacitidine”, 8 entries
- “Azacitidine (AZA)”, 2 entries
- “Eganelisib in combination with azacitidine”, 1 entry
- “NHT102”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 30 studies
- Myelodysplastic Syndromes, 18 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Hematologic Neoplasms, 1 study
- Lymphoma, T-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.